Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter to proceed with longer-acting Advate

This article was originally published in Scrip

Executive Summary

Baxter is progressing with the development of a longer-acting Advate product for the treatment of hemophilia A. The company has filed an IND for BAX 855 with the US FDA following positive Phase I results. Using PEGylation technology through a collaboration with Nektar Therapeutics, the half-life of BAX 855 in the body measured in the Phase I trial was around 1.5-fold higher compared to Advate.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel